[go: up one dir, main page]

AR065772A1 - Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. - Google Patents

Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.

Info

Publication number
AR065772A1
AR065772A1 ARP080101085A ARP080101085A AR065772A1 AR 065772 A1 AR065772 A1 AR 065772A1 AR P080101085 A ARP080101085 A AR P080101085A AR P080101085 A ARP080101085 A AR P080101085A AR 065772 A1 AR065772 A1 AR 065772A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
cycloalkyl
carbonyl
compounds
Prior art date
Application number
ARP080101085A
Other languages
English (en)
Inventor
Ying Han
Kap-Sun Yeung
John A Bender
Piyasena Hewawasam
Robert G Gentles
Thomas W Hundyma
Yong Tu
John F Kadow
Min Ding
Katharine A Grant-Young
Xiaofan Zheng
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR065772A1 publication Critical patent/AR065772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Los compuestos tienen actividad contra el virus de la hepatitis C (HCV) y son utiles en el tratamiento de los infectados con HCV. Composiciones farmacéuticas que los contienen y uso de los mismos. Reivindicacion 1: Un compuesto caracterizado porqueformula 1 en la que: R1 es CO2R5 o CONR6R7; R2 es el grupo de formulas 2; R3 es hidrogeno, halo, alquilo, alquenilo, hidroxi, benciloxi o alcoxi; R4 es cicloalquilo; R5 es hidrogeno o alquilo; R6 es hidrogeno, alquilo, alquil-SO2, alquenil-SO2,cicloalquil-SO2, (cicloalquil)alquil-SO2, haloalquil-SO2, (R9)(R10)NSO2 o (R11)SO2; R7 es hidrogeno o alquilo; R8 es hidrogeno, alquilo, cicloalquilo, (cicloalquil)alquilo, hidroxialquilo, alcoxialquilo, alquilcarbonilo, cicloalquilcarbonilo,haloalquilcarbonilo, alcoxicarbonilo, alquil-SO2, cicloalquil-SO2, haloalquil-SO2, aminocarbonilo, (alquilamino)carbonilo, (dialquilamino)carbonilo, bencilo, benciloxicarbonilo o piridinilo; R9 es hidrogeno o alquilo; R10 es hidrogeno o alquilo; R11es azetidinilo, pirrolidinilo, piperidinilo, N-(R12)piperazinilo, morfolinilo, tiomorfolinilo, homopiperidinilo, homomorfolinilo, tetrahidrofuranilo, tetrahidropiranilo, (tetrahidrofuranil)alquilo o (tetrahidropiranil)alquilo; y R12 es hidrogeno oalquilo; o una sal farmacéuticamente aceptable del mismo.
ARP080101085A 2007-03-14 2008-03-14 Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas. AR065772A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89488707P 2007-03-14 2007-03-14
US98947407P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
AR065772A1 true AR065772A1 (es) 2009-07-01

Family

ID=39477552

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101085A AR065772A1 (es) 2007-03-14 2008-03-14 Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.

Country Status (19)

Country Link
US (1) US7547690B2 (es)
EP (1) EP2118109B1 (es)
JP (1) JP5232178B2 (es)
KR (1) KR20100015304A (es)
CN (1) CN101657455B (es)
AR (1) AR065772A1 (es)
AU (1) AU2008226639B2 (es)
BR (1) BRPI0808763A2 (es)
CA (1) CA2681093A1 (es)
CL (1) CL2008000751A1 (es)
CO (1) CO6180426A2 (es)
EA (1) EA016614B1 (es)
IL (1) IL200905A0 (es)
MX (1) MX2009009473A (es)
NZ (1) NZ579342A (es)
PE (1) PE20090648A1 (es)
TW (1) TW200848058A (es)
WO (1) WO2008112473A1 (es)
ZA (1) ZA200906129B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ATE533771T1 (de) * 2007-11-20 2011-12-15 Bristol Myers Squibb Co Cyclopropylkondensierte indolobenzazepine als hcv-ns5b-inhibitoren
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
PL2238142T3 (pl) 2007-12-24 2012-11-30 Janssen R&D Ireland Makrocykliczne indole jako inhibitory wirusa zapalenia wątroby typu C
ES2416062T3 (es) * 2008-03-27 2013-07-30 Bristol-Myers Squibb Company Inhibidores de NS5B del VHC de indolobenzadiazepina condensados con pirrolidina
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
AU2009228337A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
PE20121556A1 (es) * 2009-12-07 2012-12-05 Targacept Inc 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
WO2014011863A1 (en) * 2012-07-12 2014-01-16 Targacept, Inc. Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane
SG11201500157TA (en) * 2012-07-18 2015-03-30 Bristol Myers Squibbholdings Ireland Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
AU2017233739A1 (en) 2016-03-15 2018-09-20 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
CN110028510A (zh) * 2019-05-22 2019-07-19 南京合巨药业有限公司 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法
US20220380318A1 (en) 2019-11-07 2022-12-01 Bayer Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7662809B2 (en) 2004-10-26 2010-02-16 Istituto Di Richerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP5205370B2 (ja) * 2006-05-25 2013-06-05 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors

Also Published As

Publication number Publication date
NZ579342A (en) 2011-07-29
EP2118109B1 (en) 2014-11-26
CL2008000751A1 (es) 2008-07-25
KR20100015304A (ko) 2010-02-12
MX2009009473A (es) 2009-09-15
EA200901241A1 (ru) 2010-02-26
US20080227769A1 (en) 2008-09-18
JP5232178B2 (ja) 2013-07-10
CN101657455A (zh) 2010-02-24
PE20090648A1 (es) 2009-05-29
AU2008226639B2 (en) 2012-07-19
EP2118109A1 (en) 2009-11-18
ZA200906129B (en) 2010-11-24
AU2008226639A1 (en) 2008-09-18
BRPI0808763A2 (pt) 2014-09-16
TW200848058A (en) 2008-12-16
WO2008112473A1 (en) 2008-09-18
CA2681093A1 (en) 2008-09-18
CO6180426A2 (es) 2010-07-19
JP2010521476A (ja) 2010-06-24
CN101657455B (zh) 2013-02-06
US7547690B2 (en) 2009-06-16
IL200905A0 (en) 2010-05-17
EA016614B1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
AR061053A1 (es) Inhibidores ns5b del virus de hepatitis c de indolobenzazepina fusionados a ciclopropilo
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
AR034448A1 (es) Uso de derivados de nucleosidos, dichos derivados de nucleosidos para dicho uso, composiciones farmaceuticas que los comprenden y uso de dichas composiciones
JP2010521483A5 (es)
GEP20125456B (en) Azetidines as mek inhibitors for the treatment of proliferative diseases
AR035991A1 (es) Derivados de benzimidazoles e imidazopiridinas, un procedimiento para su preparacion, composiciones farmaceuticas, un procedimiento para su preparacion, y un medicamento utiles como inhibidores de la replicacion del virus sincitial respiratorio
AR045687A1 (es) Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen
HRP20090627T1 (hr) Inhibitori hcv ns3 proteaze
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR068413A2 (es) Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
AR082201A1 (es) Bencenosulfonamidas utiles como inhibidores del canal de sodio
SG166791A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
PE20080144A1 (es) Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa
AR012488A1 (es) Un compuesto derivado de quino- y quinazolinas antagonistas del factor liberador de corticotropina, un procedimiento para su preparacion, unacomposicion que los comprende, un procedimiento para la preparacion de dicha composicion, intermediarios y el uso de dichos compuestos para la fabricacion
CO6251359A2 (es) Compuestos de indolobenzazepina sustituida por heteroarilo
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
ECSP045073A (es) Nuevos derivados de piperazina
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal